News from novartis pharmaceuticals corporation

Jun 01, 2014, 09:02 ET

Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell...

May 05, 2014, 01:21 ET

Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues

 Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in...

Apr 23, 2014, 06:15 ET

Novartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list

 Novartis Pharmaceuticals Corporation (NPC) has been named the leading company on the 14th annual DiversityInc Top 50 Companies for Diversity...

Apr 03, 2014, 07:00 ET

Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways

 Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual...

Mar 22, 2014, 08:00 ET

Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients

 Novartis today announced results from the Phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), a selective interleukin-17A...

Mar 21, 2014, 14:58 ET

Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives

Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair® (omalizumab) for the treatment of chronic idiopathic...

Jan 08, 2014, 18:50 ET

Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety

 Patient safety and well-being are the highest priority at Novartis Pharmaceuticals Corporation (NPC). NPC is dedicated to improving patient...

Jun 04, 2013, 08:00 ET
Join Phil Keoghan and Novartis to raise awareness of MS.  (PRNewsFoto/Novartis Pharmaceuticals Corporation)

TV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign

Phil Keoghan, host of "The Amazing Race" and founder of No Opportunity Wasted (NOW), joins Novartis Pharmaceuticals Corporation for the third year...

May 30, 2013, 01:15 ET

Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC

 People with relapsing multiple sclerosis (MS) reported greater treatment satisfaction after starting the oral treatment Gilenya®...

May 10, 2013, 01:20 ET

Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis

 Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active...

Apr 26, 2013, 18:52 ET

Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts

 Novartis Pharmaceuticals Corporation (NPC) disputes the allegations made by the US Attorney's Office (USAO) for the Southern District of New...

Mar 22, 2013, 20:54 ET

FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US

Novartis announced today that the US Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder) 28...

Mar 21, 2013, 02:16 ET

New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies

New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first oral disease...

Feb 24, 2013, 13:17 ET

Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy

 Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe...

Jan 23, 2013, 16:00 ET

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia

 Novartis announced today that the US Food and Drug Administration (FDA) has approved Exjade® (deferasirox) for the treatment of chronic...

Jan 10, 2013, 18:35 ET

Phase III data in The Lancet show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC

Data published today in The Lancet showed that patients on Afinitor® (everolimus) tablets with non-cancerous kidney tumors known as renal...

Dec 19, 2012, 17:00 ET

NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis

The New England Journal of Medicine (NEJM) published today the results of two Phase III trials, and both show ACZ885 (canakinumab) provided...

Nov 06, 2012, 19:51 ET

Novartis Phase III Study Shows RLX030 Improved Symptoms and Reduced Deaths by One-Third in Patients with Acute Heart Failure

 The Phase III RELAX-AHF study has shown that investigational RLX030 (serelaxin) improved symptoms and reduced deaths by one-third at the end...

Oct 16, 2012, 16:30 ET

Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on

 More than five million people in the United States have Alzheimer's disease, and that number is expected to triple by 2050.2 As the prevalence...

Sep 26, 2012, 01:00 ET

Novartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer

De acuerdo a investigaciones llevadas a cabo por la Alzheimer's Association de los EE. UU., la cantidad de hispanos de edad avanzada con...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review